Company Overview: GeoVax HIV/AIDS Vaccines

Industry News

4 Aug

GeoVax Reports 2015 Second Quarter Financial Results and Provides Corporate Update

ATLANTA, GA–(Marketwired – Aug 4, 2015) – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines using its novel platform technology, announced its financial results for the three and six months ended June 30, 2015 and provided the following corporate update. Ebola/Marburg Vaccine Program: In April 2015, GeoVax...

Read more

27 May

GeoVax to Present at the LD Micro Invitational Conference

GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola virus and HIV using its novel platform technology, today announced that it will present at the LD Micro Invitational Conference on June 1, 2015 at the Luxe Sunset Boulevard Hotel in Los Angeles. The Company’s...

Read more

19 May

GeoVax to Present at the 2015 Marcum MicroCap Conference

GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola virus and HIV using its novel platform technology, today announced that it will present at the 2015 Marcum MicroCap Conference on Wednesday, May 27, 2015 in New York City at the Grand Hyatt Hotel. The...

Read more

13 May

GeoVax Reports 2015 First Quarter Financial Results and Provides Corporate Update

Ebola/Marburg Vaccine Program Advances With NIH Collaboration; HIV Vaccine Program Proceeding Toward Pivotal Trial GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the three months ended March 31, 2015, and provided the following corporate...

Read more

14 Apr

GeoVax to Seek Dual Pathway for Advancing Its HIV Preventive Vaccine

Strategy Intended to Accelerate Development of an HIV Vaccine for the Americas and Western Europe GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today announced its intention to pursue a dual pathway for advancing its preventive...

Read more

13 Apr

HIV vaccine from GeoVax Labs advances in clinical trials

GeoVax Labs’ vaccine candidate for HIV has advanced to the next stage of clinical trials, the laboratory announced on Tuesday. In this trial, 100 individual volunteers who had participated in a previous trial, concluded in 2012, will be utilized to test the vaccine candidate’s efficacy for increasing antibodies in...

Read more

9 Apr

GeoVax Provides Details of Presentation at World Vaccine Congress

GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today provided details of the talk presented by its Chief Scientific Officer, Harriet L. Robinson, Ph.D., at the World Vaccine Congress in Washington, D.C. The title of her...

Read more

1 Apr

GeoVax Provides Update on Its HIV Vaccine Program

New Clinical Trial Planned With HVTN and NIH Support; Concept Protocol Approved for HVTN 114 GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV, today announced that the HIV Vaccine Trials Network (HVTN) has assigned a trial number, HVTN 114, to the...

Read more

31 Mar

GeoVax’s Chief Scientific Officer to Speak at World Vaccine Congress

GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines for Ebola and HIV using its novel platform technology, today announced that Chief Scientific Officer Dr. Harriet L. Robinson, is invited to speak at the World Vaccine Congress to be held April 7-9, 2015 in Washington, DC. Dr....

Read more

Page 1 of 3123

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address